<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00729495</url>
  </required_header>
  <id_info>
    <org_study_id>D1120C00007</org_study_id>
    <nct_id>NCT00729495</nct_id>
  </id_info>
  <brief_title>Phase I Study to Evaluate Bioavailability of Overencapsulated Celecoxib</brief_title>
  <official_title>Phase I, Randomized, Open-Label, 2-Way Crossover Study to Evaluate Relative Bioavailability of Single Oral Dose of Celecoxib Administered as Marketed Product, or Overencapsulated Capsule in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>POZEN</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I study designed to test the hypothesis that overencapsulated celecoxib 200 mg qd is
      bioequivalent to commercial celecoxib 200 mg qd. Approximately 90 healthy volunteers will be
      randomized to yield approximately 80 completers. The study is an open label, randomized,
      2-way crossover with single dosing followed by a 7-day washout period between treatment arms
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>pre-dose, baseline and multiple times post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Throughout study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Healthy Volunteer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>marketed celecoxib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>overencapsulated celecoxib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib</intervention_name>
    <description>dose form</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female subjects 18-55 yrs. of age (inclusive) at Screening Visit

          -  Body Mass Index (BMI) of greater than or equal to 19 to less than or equal to 30 kg/m2
             and weight of greater than or equal to 50 to less than or equal to 100 kg

          -  Clinically normal physical exams and laboratory measurements

        Exclusion Criteria:

          -  Subject has received another investigational drug within 4 weeks preceeding this study
             or planning to participate in another study at any time during the period of this
             study

          -  Any significant medical or psychiatric condition that could affect the interpretation
             of the PK data, or which otherwise would contraindicate participation in a clinical
             trial

          -  Any GI disease, abnormality or gastric surgery that may interfere with gastric
             emptying, motility and drug absorption

          -  Subject who has donated a unit of blood or plasma within 3 months prior to the
             Screening Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Sostek, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Billings, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bio-Kinetic Clinical Applications, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 5, 2008</study_first_submitted>
  <study_first_submitted_qc>August 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2008</study_first_posted>
  <last_update_submitted>May 12, 2009</last_update_submitted>
  <last_update_submitted_qc>May 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2009</last_update_posted>
  <responsible_party>
    <name_title>Mark Sostek, MD, Medical Science Director, Development Project</name_title>
    <organization>AstraZeneca Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Phase I,</keyword>
  <keyword>Healthy</keyword>
  <keyword>Volunteer</keyword>
  <keyword>Study</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

